Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10961250 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US10472365 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9914738 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9777007 | ACACIA | Short-acting benzodiazepine salts and their polymorphic forms |
Jul, 2027
(4 years from now) | |
US9737547 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US10722522 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US10342800 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US10052334 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Nov, 2031
(8 years from now) | |
US10195210 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Nov, 2031
(8 years from now) | |
US9561236 | ACACIA | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
Apr, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 6, 2025 |
NCE-1 date: 2024-10-06
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER;INTRAVENOUS
16
United States
8
European Union
5
China
4
Korea, Republic of
4
Hong Kong
3
United Kingdom
3
Japan
2
Portugal
2
Spain
2
Slovenia
2
Poland
2
Australia
2
Denmark
1
Germany
1
Russia
1
Brazil
1
Croatia
1
Austria
1
Mexico
1
EA
1
Lithuania
1
Canada
1
Hungary
1
RS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic